Skip to main content
SpringerLink
Log in

Monitoring abiraterone levels may be cost effective

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2018 euros

Reference

  • ten Ham RMT, et al. Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients. Value in Health : 11 Sep 2020. Available from: URL: https://doi.org/10.1016/j.jval.2020.04.1838

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Monitoring abiraterone levels may be cost effective. PharmacoEcon Outcomes News 863, 22 (2020). https://doi.org/10.1007/s40274-020-7176-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7176-8

Search

Navigation